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Oral isosorbide dinitrate has been widely used to lover
elevated left ventricular filling pressure In patients with
chronic heart failure. Although the recu emended dose
of
this drug Is 40 mg every 6 h, failure to respond to this dose
ha been observed in many patients with heart failure. In
the present study the Incidence of resistance to isosorbide
dinitrate was evaluated and an attempt war made to
idenfity baseline hemadynuink predictors for this phenon,
cum In 50 patterns with severe chronic heart Failure due to
kft ventricular systolic dysfunction (mom left ventricular
ejection traction, 0.23 x 0.00).
Twenty-seven (54%) of The 50 patients responded 10 a
mg
of isoserbi a dlnitrate (>20% decrease i mean pohoo-
nmy artery wedge pressure sustained a1 b) and 23 patients
(46%) tailed to respond . Noarespondes to 40 mg of
luonoebide diltrale had a significantly Wow laadlew right
Wind pressure than did responders (14 t 5 verses 10 3
6
m Hg, p < 0.02). too addition, all 7 patients with a
heartier right alibi pressure of <7 mm Hg and 12 of 14
patents with a baseline right aerial pressure <10 m Hg
Organic nitrates have been widely used in the treatment of
acute and chronic heart failure due to left ventricular dys .
function (1-4). Their beneficial hemodynamie effect is pri-
marily due to their venodilating action and concomitant
ability to reduce left ventricular filling pressure
(3,5,6) .
However, hemodynamic resistance to organic nitrates in
patients with heart failure is dot infrequent. Administration
of nitroglycerin in t';e sublingual (7,8), transdermal (8,9)
and
intravenous (10-12) routes were reported to result in failure
to decrease left ventricular filling pressure in I I to 56% of
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patients . Although oral isosorbide dinitrate is the nitrate
preparation most commonly investigated and used in the
treatment of heart failure, there has been no systematic
evaluation of the incidence of resistance to this drug in
patients with chronic severe heart failure. This study was,
therefore, undertaken to define the incidence of hnledy-
namic resistance to isosorbide dinitrate and to attempt to
identify baseline hemodynamic predictors of such resistance
in a large number of patients with chronic severe heart
failure.
Methods
study patents. The study group consisted of 50 patients
(34 men and 16 women) aged 22 to 78 year (mean 52 ± 14)
with chronic severe hen famine due to left ventf ukw
systolic dysfunction who were admitted to the hospital with
worsening symptoms. The cause of heart failure was idio-
135-t89r/ma t.50
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pathic or alcoholic dilated cardiomyopathy in 30 patients,
coronary artery disease in 10 and long-standing hypertension
in 10. The mean duration of symptoms was 30 ± 34 months
(range I month to 13 years) ; no patient had primary valvular
disease or clinical evidence of active myocardial ischemia at
the time of study . All patients were in New York Heart
Association functional class III or IV . Left ventricular
ejection fraction was quantified by contrast or radionuclide
ventriculography in 45 patients and ranged from 8 to 39%
unean 23 ± 8%) ; in the remaining 5 patients left ventricular
systolic dysfunction was confirmed by echocardiography .
Hemodynamic measurements and computations . Right
heart catheterization was performed with a balloon-tipped,
triple lumen Swan-Ganz catheter . Pressures in the right
atrium and pulmonary artery and left ventricular filling
pressure, determined indirectly from the mean pulmonary
artery wedge pressure, were recorded on Electronics for
Medicine VR-12 or AR-6 recorders ; mean pressures were
obtained with the use of electronic integration . Heart rate
was determined from the electrocardiographic (ECG) re-
cording and arterial blood pressure was measured by the
standard cuff method . Cardiac output wa . determined by
thermodilution as previously described (13) . Calculations of
mean arterial blood pressure, cardiac index, stroke volume
index, stroke work index, systemic vascular resistance and
pulmonary vascular resistance were performed by standard
formulas (14) .
Serum levels of isosorbide dinitrate were
determined by gas liquid chromatography (15) .
Study protocol . After clinical stabilization, right heart
catheterization was performed at least 24 h before the onset
of the study to guard against previously reported spontane-
ous hemodynamic changes after the procedure (16). All
forms of organic nitrates and other long-acting vasodilators
were withheld for at least 24 h ; stable doses of digitalis and
oral diuretics were continued throughout the study . On the
day of the study, baseline hemodynamic measurements were
performed every 30 min until two consecutive measurements
with <10% variation were obtained; the values determined
at the last measurement were used as baseline data. All
patients were then given 40 mg of oral isosorbide dinitrate
and repeat hemodynamic measurements were obtained
hourly for 4 h
. In the last 17 patients, mixed venous blood
was obtained hourly for de ermination of serum isosorbide
dinitrate level
. In the patients wh,) failed to respond to 40
mg, 80 to 120 mg was admininered 4 to
24 h later, and repeat
hemodynamic measurements were perfoin
ed in an identical
fashion . The study was continued until the desired response
was achieved or a maximal do v of 120 mg was administered .
Hemodynamic response to isosoroide dinitrate was defined
as a 020% decrease in pulmonary artery wedge pressure
sustained for z!
: I h. The definition of response was based on
a previously reported (12) coefficient of variation of 17% in
serial measurements over 24 h in a group of patients with
IACC Vol . 12, No. 4
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Flgare 1. Percent change from baseline in mean pulmonary artery
wedge (PAW) pressure in responders (solid bars) and nonresponders
(hatched bars) to 40 mg of oral isosorbide dinitrate .
chronic heart failure and similar hemodynamic profile
treated with placebo .
Statistical analysis . All comparisons between responders
and nonresponders were made using two-tailed, unpaired t
tests . In instances where the hypothesis of normality was
rejected at the 0
.05 level, a nonparametric, Wilcoxon non-
paired rank sum test was substituted . Analysis was per-
formed with the use of the CLINFO system and the SAS
statistical package on the IBM 370 system at the University
of Southern California. All values are expressed as mean ±
I SD. A p value <0 .05 was considered statistically signifi-
cant.
Results
Response to 40 mg of lsmarbide dinitrate. After an oral
dose of 40 mg of isosorbide dinitrate, 27 (54%) of the 50
patients demonstrated a sustained decrease (±20% for
N I h)
in mean pulmonary artery wedge pressure, whereas in 23
patients (46%) a similar effect on the pulmonary artery
wedge pressure or any other hemodynamic variables was not
demonstrated
. Figure I demonstrates the difference in per-
cent change in mean pulmonary artery wedge pressure after
administration of isosorbide dinitrate in responders and
nonresponders to the 40 mg dose . A significant difference
was found between the two groups at I h (-28 ± 14% versus
-14 ± 13%, p < 0.01), 2 h (-32 ± 14% versus 6 t 8%, p <
0.000001), 3 h (-25 ± 17% versus 3 ± 11%, p < 0.00001) and
4 h (-21 ± 18% versus -5 ± 14%, p < 0 .001) .
Table I compares baseline clinical and be-wodynmic
variables in responders and nonresponders
to 40 mg of
isosorbide dinitrate . No significant difference existed be-
tween the two groups with regard to chronicity of symptoms
or severity of left ventricular dysfunction
. Baseline mean
right atria) pressure was significantly higher in nonrespond-
ers than in responders (14 ± 5 versus 10 ± 6 min Hg, p <
0.02) . All other baseline hemodynamic variables were com-
parable between the two groups .
CI = cardiac index; HR = heart rate; LVEF =
left
vemricular jeclion
fraction ; MAP = mean arterial pressure; PA = pulmonary arterial pressure :
PAW = pulmonary artery wedge pressure ; PVR = pulmonary vascular
resistance
; RA = right atria] pressure ; SVI =
stroke volume index : SVR =
systemic vascular resistance : SWI = stroke work index .
Figure 2 demonstrates individual baseline values of mean
right aerial pressure in responders and nonresponders to 40
mg of isosorbide dinitrale . Although marked overlap is seen
between the two groups, all seven patients who had an initial
mean right atrial pressure of <7 mm Hg responded to the 40
mg dose . Furthermore, of 14 patients with an initial right
atria) pressure of < 10 mm Hg, 12 (86%) responded to the 40
mg dose. Of 43 patients with elevated right atria) pressure
(>7 mm Hg), 20 (47%) responded and 23 did not . The
Figure
2
. Individual values for mean right atria) pressure in 27
responders and 23 nonresponders to 40 mg of isosorbide dinitrate .
30
RESPONDERS NON-RESPONDERS
(N .27)
	
(N
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Figure 3. Response to high dose (80 to 120 mg) isosorbide dinitrate
(ISDN) in 23 nonresponders to the 40 mg dose . DIC = excluded
from study .
response pattern ws unpredictable with marked overlap
between the two groups.
Response to So to 120 mg of iwsurhide dinitrate
. Figure 3
outlines the response to higher dons of isosorbide dinitrate
in patients who did not respond to 40 mg of isosorbide
dinitrate . One of the 23 nonresponders to the 40 mg dose was
excluded from study because of catheter malfunction. Four-
teen of the remaining 22 patients received 80 mg 4 to 24 h
after the 40 mg dose; 2 of these patients responded to 80 mg .
The 12 nonresponders to 80 mg, as well as the other 8
nonresponders to 40 mg, received 120 mg of the drug . Of
these 20 patients, 8 responded to the 120 mg dose and 12 did
not. Overall, therefore, 10 (45%) of the 22 nonresponders to
40 mg of isosorbide dinitrate exhibited a sustained decrease
in mean pulmonary artery wedge pressure after administra-
tion of 80 to 120 mg of the drug and 12 patients (55%) failed
to respond to even the 120 mg dose
.
Thus, of the patients with an elevated mean right atria)
pressure, about one-half responded to 40 mg of isosorbide
dinitrate, about a quarter responded to 80 to 120 mg and a
quarter failed to respond
. A comparison of baseline hemo-
dynamic values in responders and nonresponders to high
dose isosorbide dinitrate showed no significant difference
between the two groups in any of the measured or calculated
hetnodynamic variables . Mean right atrial pressure was 15 t
5 mm Hg in the responders and 14 ± 5 mm Hg in the
nonresponders (p = NS) .
Isosnrhide dinitrate serum kvgin. Determinations of se-
rum levels of isosorbde dinitrate were performed after the
administration of 40 mg in 17 patients, 9 responders and 8
nonresponders
. No significant difference was found in peak
drug level and the area under the curve as measured over 4
It between responders and nonresponders (44 ± 36 versus 32
IACC Vol . 12 . No. 4
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as Pr8
Reupunders Nonresponders
222 P1.
to = 27) In = 23, p value
.1.
Symptom duration Imo) 37 ± 40
22
x 26 NS
:4R
.
LVEFIn=451 0.2300.07 24 0.08 NS
x
ISO. .-
Mean pressures (mm Hg)
RA 1006 1405 <0 .02
Resronsn / \NeRiawae
PAW 27 *_ 7 30 t 6 NS
PA 40 0 8 41 x 8 NS
2- . 12 Pit,
CI Iliterslndn per mc) 2 .1 0 0 .5 19 t 0.4 NS
SVI (mpm') 24 t 7 21 0 7 NS
HR (beatslmin) 91 a 16 94 t 16 NS
MAP (mm Hg) 95 '- 14 92 x 14 NS
,sun Izonq
SVR (dyoenn em-1) 1827 t 491 1718 0 407 NS
IN-201
PVR (dynes, s398 0 557 260- 146 NS
SWIisMM') 23tIt I8--9 NS
S .,. 12-
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± 19 og/ml and 80 ± 52 versus 59 ± 29 ng/ml, respectively)
.
In six patients, isosorbide dinitrate plasma level was mea-
sured after the administration of both the 40 and the 120 mg
dose . Peak plasma level was significantly higher after the
higher dose (127 ± 36 versus 32 ± 20 ng/ml, p < 0.001).
Discussion
isosorbide dinitrate has been the nitrate preparation most
commonly employed in the treatment of chronic heart
failure
(1-4).
This drug has been shown to improve hemodynamics,
enhance exercise capacity and, in combination with hydra-
lazine, prolong survival in patients with severe heart failure
(2-6,17-19). The beneficial effect of isosorbide dinitrate as
well as other organic nitrates in the therapy of heart failure is
derived more from their venodilating effect and the resulting
decrease in ventricular filling pressure than from their vaso.
relaxing effect on the systemic arterial bed (3,5,6). The dose
of isosorbide dinitrate commonly used to treat heart failure is
40 mg, usually administered four times daily (2,5,6.18-20)
;
this dose is somewhat higher than that frequently used to
treat angina pectoris (21,22) .
Incidence of nitrate resistance . The present study demon-
strates a high incidence of hemodynamic resistance to oral
isosorbide dinitrate in 50 consecutive
patients with severe
chronic congestive heart failure
. Almost half of the patients
did not respond to the commonly recommended dose of 40
mg isosorbide dinitrate and almost
one-fourth did not re-
spond even to doses as high as 120 mg . Although this study
the fast atica5pi iu evaiuaie hemodynamic responsiveness
to oral isosorbide dinitrate in a'irge group of patients with
chronic heart failure, our findings are in support of previ-
ously reported data describing resistance to organic nitrates .
Armstrong et al. (10) reported failure to attain a 25%
reduction in mean pulmonary artery pressure with intrave-
nous nitroglycerin in doses in excess of 400
pg/min
in 31% of
patients, the majority of whom had had recent onset of heart
failure after an acute myocardial infarction
. A somewhat
higher incidence of resistance was reported by Magrini and
Niarchos (7). who found about half of the patients with acute
heart failure to be unresponsive to sublingual nitroglycerin .
Other recent reports (8,9,11,12) have demonstrated
a 20 to
27% nonresponse rate to transdermal nitroglycerin and an I I
to 13% nonresponse rate to intravenous nitroglycerin in
patients with chronic heart failure . A lower incidence of
resistance to isosorbide dinitrate at
a dose of 40 mg was
described by Franciosa and Cohn (20) in a small
number of
patients with chronic heart failure ; these investigators
found
failure to exhibit a 20% decrease in pulmonary artery wedge
pressure in only 1 (5%) of 19 patients
. The explanation for
the discrepancy between these results
and our findings is
probably related to more severe
disease and the stricter
definition of hemodynamic response
in our study . In addi-
tion, because insertion of a pulmonary artery catheter and
1ACC Vol. 12, No.4
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drug administration were performed on the same
day, some
of the reduction in pulmonary artery wedge pressure found
by Franciosa and Cohn (20) could have been due to the
reported (16) spontaneous decrease in this variable after
catheter insertion .
Potential mechanisms for nitrate resistance . Although re-
sistance to organic nitrates has been described by several
investigators, the mechanism of this phenomenon remains to
be elucidated. In our attempt to separate responders from
nonresponders, we found significantly higher values of right
atrial pressure in nonresponders to 40 mg of isosorbide
dinitrate . Similar findings were reported by Armstrng et al
.
(10) and Packer et al . (8), who studied the hemodynamic
effects of nitroglycerin in patients wth acute and chronic
heart failure . Pretreatment values of right atrial in ^ssure
have also been used to predict response to conve-ting
enzyme inhibitors in patients with heart failure (23)
.
Thsse
findings may suggest that maximal stretch of capacitance
vessels might play a role in resistance to nitrates and othe•
venodilating drugs. Elevated right atria) pressure has also
been reported (24) to influence responsiveness to hydrala-
zine in patients with heart failure and was suspected to
impair gastrointestinal drug absorption ; our study, however,
shows no significant difference in isosorbide dinitrate blood
levels between responders and nonresponders . Magrini and
Niarchos (7) suggested that increased amounts of sodium
and water within the vascular walls or increased external
mechanical compression due to accumulation of rabcutane-
ous fluid may impair responsiveness . They found a high
incidence of resistance to nitroglycerin in patients with acute
heart failure and peripheral edema . which was reversed
when edema was cleared with dinresis . This suggested
mechanism of nitrate resistance
was probably not opera-
tional in our study because all patients were in a stabilized
state with correction of peripheral edema before enrollment
in the study . The hemodynamic effect of hydralazine was
suggested (25) to be limited by activation of vasoconstrictor
mechanisms in some patients . Similarly, differences in acti-
vation of neurohoraoral systems could explain differences in
response to isosurbide dinitrate and the possibility should be
further investigated
.
Our study demonstrates a relation between the oral
isosorbide dinitrate dose administered and hemodynamic
response
because half of nonresponders to the initial 40 mg
dose responded to a higher dose
. However, failure
of 24% of
patients to respond to a dose as high as
120 mg isosorbide
dinitrate supports previous reports (8) suggesting that some
patients are resistant to nitrates regardless of the dose given.
This finding may suggest that nitrate resistance can occur at
the cellular level in some patients . Organic nitrates bind to
receptors on smooth muscle cells, and through oxidation of
sulfhydryl groups and conversion to s-nitrosothiols they
augment guanylate cyclase activity, leading to production of
cyclic guanosine monophosphate and ultimately to vasodila-
JACC Vol. 12, No. 4
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Lion (26,27) . Availability of sulthydryl groups has beer .!,.own
to play a role in nitrate responsiveness . Recent studies (28,29)
have shown potentiation of nitroglycerin-induced peripheral
and coronary dilatory effect and reversal of nitrate tolerance
in patients with heart failure with N-acctylcysteine . a source
of sulthydryl groups . More clinical data, however, are needed
for further understanding of the potential role of sulfhydryi
group donors in reversing hemodynamic resistance to organic
nitrates in patients with heart failure .
Limitations of study. There are several potential limita-
tions to the present study. First, the majority of our patients
had been receiving a long-acting nitrate before enrollment in
the study
. Continuous nitrate therapy can result in arrears-
don of hemodynamic effects as a result of development of
tolerance (12,30-32)
. Although tolerance in initially respon-
sive patients could have been interpreted in our study as
resistance, all forms of nitrates were discontinued in our
patients m24 h before commencement of the study. Thisl
nitrate-free interval has been shown to be a sufficicot time
period for reversal of nitrate tolerance
('_1j.
An additional
potential limitation of our e?uJy may be related to the
definition of r°s ;Atnse to isosorbide dinitrate therapy. At-
though reduction in mean pulmonary artery wedge pressure
at rest is an adequate marker for hemodynamic response to
isosorbide dinitrate, the effect of this drug on symptoms,
exercise capacity and survival may not always correlate with
the change in this hemodynamic variable. Finally, none
of
our patients received doses of
isosorbide dinitrate
>120 mg;
it is conceivable that higher doses would have increased the
incidence of hemodynamic response to therapy
. Such doses,
however, would far exceed those commonly recommended
and employed in patients with heart failure .
Conclusions. The present study demonstrates resistance
to oral isosorbide dinitmte in a substantial number of pa-
tients with chronic severe heart failure . Our data show lack
of hemodynamic response to the commonly utilized dose of
40 mg in almost half of the 50 consecutive patients with
severe chronic left ventricular dysfunction . Hemodynamic
response to such a dose can be predicted by the clinician in
patients with normal right atrial pressure . However, in
patients with elevated right atria] pressures, hemodynamic
response is unpredictable. Only half of these patients re-
sponded to 40 mg of oral isosorbide dinitrate whereas about
a quarter of them require higher doses (80 to 120 mg) and the
other quarter do not respond to a dose as high as 120 mg and
may need to be
treated with other vasodilating agents
.
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